Littérature scientifique sur le sujet « Immune check point inhibitor »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Immune check point inhibitor ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Immune check point inhibitor"
Jaswani, Tamika S., Meeta Desai, Douglas Grider et Jonathan M. Bern. « Immune Check Point Inhibitor-induced Colitis ». American Journal of Gastroenterology 112 (octobre 2017) : S858—S860. http://dx.doi.org/10.14309/00000434-201710001-01575.
Texte intégralBobart, Shane A., Itunu Owoyemi, Joseph Grande, Nelson Leung et Sandra M. Herrmann. « Immune Check Point Inhibitor–Associated Endothelialitis ». Kidney International Reports 5, no 8 (août 2020) : 1371–74. http://dx.doi.org/10.1016/j.ekir.2020.05.027.
Texte intégralAshour, Tarek, Georges Nakhoul, Pradnya Patil, Pauline Funchain et Leal Herlitz. « Immune Check Point Inhibitor–Associated Glomerulonephritis ». Kidney International Reports 4, no 2 (février 2019) : 355–59. http://dx.doi.org/10.1016/j.ekir.2018.10.017.
Texte intégralKumar, Aswini, Maximilian Lee et Talhat Azemi. « IMMUNE CHECK POINT INHIBITOR MYOCARDITIS MIMICKING ACS ». Journal of the American College of Cardiology 73, no 9 (mars 2019) : 2681. http://dx.doi.org/10.1016/s0735-1097(19)33287-5.
Texte intégralNilajgi, Shalini, Nicholas Kasmeridis et Kichendasse Ganessan. « A Case Of Immune Check Point Inhibitor - Induced Hypophysitis ». Journal of the Endocrine Society 5, Supplement_1 (1 mai 2021) : A560. http://dx.doi.org/10.1210/jendso/bvab048.1142.
Texte intégralSuchý, David. « Immune-related adverse events associated with immune check-point inhibitors ». Klinická farmakologie a farmacie 33, no 3 (28 octobre 2019) : 20–24. http://dx.doi.org/10.36290/far.2019.019.
Texte intégralMarthey, Lysiane, Raef Abdallah, Christophe Bellanger, Clément Bresteau, Antoine Meyer, Aurélien Amiot et Franck Carbonnel. « Immune check-point inhibitors related enterocolitis ». Hépato-Gastro & ; Oncologie Digestive 30, no 8 (octobre 2023) : 826–32. http://dx.doi.org/10.1684/hpg.2023.2641.
Texte intégralJohncilla, Melanie, Shilpa Grover, Xuchen Zhang, Dhanpat Jain et Amitabh Srivastava. « Morphological spectrum of immune check‐point inhibitor therapy‐associated gastritis ». Histopathology 76, no 4 (18 février 2020) : 531–39. http://dx.doi.org/10.1111/his.14029.
Texte intégralKim, Jin Young, Chi Heum Cho et Hong Suk Song. « Targeted therapy of ovarian cancer including immune check point inhibitor ». Korean Journal of Internal Medicine 32, no 5 (1 septembre 2017) : 798–804. http://dx.doi.org/10.3904/kjim.2017.008.
Texte intégralVergne-Santiago, Norma, Ernesto Jos E. Sola Sanchez et Michelle Marie Mangual Garcia. « Immune Check Point Inhibitors Triggering Non Autoimmune Polyendocrinopathy ». Journal of the Endocrine Society 5, Supplement_1 (1 mai 2021) : A136—A137. http://dx.doi.org/10.1210/jendso/bvab048.275.
Texte intégralThèses sur le sujet "Immune check point inhibitor"
Dréan, Raphaelle. « Développement de nano-anticorps antagonistes du point de contrôle immunitaire ILT4 pour une application en immunothérapie antitumorale ». Electronic Thesis or Diss., Sorbonne université, 2022. http://www.theses.fr/2022SORUS446.
Texte intégralILT4 (Immunoglobulin-Like Transcript 4) is an immune checkpoint receptor mainly expressed by myeloid immune cells. In cancer context, ILT4 participates in tumor development by maintaining a protumoral immuno-microenvironment and directly promoting tumor cell proliferation. ILT4 interaction with the non-classical MCH class I molecule HLA-G induces an immunosuppressive microenvironment by promoting tolerogenic myeloid cells. Moreover, the ectopic expression of ILT4 has been reported in several solid tumors. The activation of ILT4 by Angiopoietin-like-2 (ANGPTL2) promotes non-small cell lung tumor cell proliferation and inhibits cell apoptosis. Targeting this new immune checkpoint with blocking antibodies is therefore a promising cancer immunotherapy approach. In light of several drawbacks of classical IgG blocking antibodies in solid cancer, we investigated the potential of VHH-based inhibitors. This small monoclonal antibody format, derived from camelid homodimeric antibodies, combine the binding capacities of antibodies to the properties of small molecules. After immunization of an alpaca and phage-display screening, we selected a VHH with high affinity and specificity to ILT4 that inhibits the interaction of the receptor with both ligands. We validated the VHH’s biological antagonist activity on tumor cells and monocyte-derived pro-tumoral M2 like macrophages in vitro. These results support the potential of this new VHH-based antibody targeting ILT4 in cancer immunotherapy
Fournel, Ludovic. « Influence Du Cisplatine sur l'expression du Check-Point Immunitaire PD-1/PD-L1 Dans Le Cancer Broncho-Pulmonaire Non A Petites Cellules Cisplatin Increases PD-L1 Expression and Optimizes Immune Check-Point Blockade in Non-Small Cell Lung Cancer Modulation of Lung Cancer Cell Plasticity and Heterogeneity with the Restoration of Cisplatin Sensitivity by Neurotensin Antibody ». Thesis, université Paris-Saclay, 2020. http://www.theses.fr/2020UPASS077.
Texte intégralDespite many advances in the recent years in the therapeutic management of bronchopulmonary cancer, it remains the leading cause of death linked to cancer in the world. The major challenge for this disease is therefore to develop new treatments and optimize the use of existing drugs, in particular platinum salts. The number of clinical protocols testing combined therapies including immune check-point inhibitors and platinum salts is currently increasing in lung cancer treatment, however preclinical studies and rationale are often lacking. Here, we evaluated the impact of cisplatin treatment on PD-L1 expression analyzing the clinicopathological characteristics of patients who received cisplatin-based neoadjuvant chemotherapy followed by surgery and showed that cisplatin-based induction treatment significantly increased PD-L1 staining in both tumor and immune cells from the microenvironment. Twenty-two patients exhibited positive PD-L1 staining variation after neoadjuvant chemotherapy; including 9 (23.1%) patients switching from <50% to ≥50% of stained tumor-cells. We also confirmed the up-regulation of PD-L1 by cisplatin, at both RNA and protein levels, in nude and immunocompetent mice bearing tumors grafted with A549, LNM-R, or LLC1 lung cancer cell lines. Up-regulation of PD-L1 by cisplatin involved the PI3K / AKT signaling pathway.The combined administration of anti-PD-L1 antibodies (3mg/kg) and cisplatin (1mg/kg) to mice harboring lung carcinoma significantly reduced tumor growth compared to single agent treatments and controls. Overall, these results suggest that cisplatin treatment could synergize with PD-1/PD-L1 blockade to increase the clinical response, in particular through early and sustainable enhancement of PD-L1 expression. Simultaneously, we were able to develop a targeted anti-neurotensin therapy to block its paracrine effects which stimulate proliferation, growth, and metastatic potential of lung tumor cells. Anti-neurotensin antibodies also improved the sensitivity to cisplatin of previously resistant tumors by mechanisms which probably involve increased influx and decreased efflux of platinum at the intra-nuclear level where resides its target DNA. All of these results provide a rationale for carrying out clinical trials involving cisplatin and aiming, by various ways, to improve the effectiveness of systemic treatments for non-small cell broncho-pulmonary cancers
Grosjean, Iris. « SQSTM1, une protéine de plateforme à la croisée de la réponse aux dommages à l’ADN et de la réponse à l’immunothérapie dans le cancer : rôles des rétrovirus endogènes ». Electronic Thesis or Diss., Université Côte d'Azur, 2020. http://www.theses.fr/2020COAZ6037.
Texte intégralNon-small cell lung cancer (NSCLC) is the deadliest cancer in the world, due to acquired resistance to genotoxic chemotherapy and radiotherapy (DNA-damaging agents, named DDAs hereafter) and targeted therapies. Immunotherapy (including immune checkpoint inhibitors (ICIs)) is a real revolution in patient care. This strategy has indeed had a positive impact, turning into treatable advanced cancers without "actionable" targets that were considered incurable. Survival at 5-year has increased from 5% with conventional treatment to 20% with immunotherapies and up to 50/60% for melanoma and lung cancer with therapies combining ICIs and DDAs. The current challenge in clinical trials is to develop combined therapeutic strategies that increase efficacy while limiting resistance to different treatments. Elucidating resistance mechanisms is essential to propose new robust predictive biomarkers and new therapeutic approaches to improve the efficacy of ICIs.We have hypothesized that resistance to DDAs and ICIs is mediated by intrinsic tumor mechanisms, some of which may be shared. Thus, we have studied the action of DDAs and their molecular consequences that lead to immune evasion. Through three complementary approaches (in silico, in vivo on patient cohorts and in vitro), we identify the p62/SQSTM1 scaffold protein as a key molecular mediator capable of predicting and controlling sensibility to DDAs and ICIs. We report for the first time that SQSTM1 causes a "HOT" tumor immune profile, while downregulating DNA repair mechanisms. In addition, SQSTM1 is essential for the DDAs-induced reactivation of human endogenous retroviruses (hERVs). Downstream, hERVs induce an innate antiviral response, resulting in the expression of interferons, MHC-I and PD-L1, leading to tumor immune evasion.In conclusion, i) we propose SQSTM1 as a predictive biomarker for selecting patients who may benefit from ICI plus DDA combination strategies, and ii) we highlight a biological rationale for the efficacy of such strategies in refractory lung cancer, aimed at promoting their use and thus improving the prognosis of NSCLC
Munivenkata, Swamy Preethi. « Combined CTLA-4 and PD-1 inhibition a single institute in-depth analysis of toxicity and efficacy in patients treated at the Dana-Farber Cancer Institute ». Thesis, 2017. https://hdl.handle.net/2144/26950.
Texte intégralChapitres de livres sur le sujet "Immune check point inhibitor"
Patel, Anush, Haisam Abid et Amrat Kumar. « The Endocrinological Side Effects of Immunotherapies ». Dans Advances in Precision Medicine Oncology. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96491.
Texte intégralThompson, John F., Richard A. Scolyer et Richard F. Kefford. « Skin cancer : melanoma ». Dans Oxford Textbook of Oncology, 674–89. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199656103.003.0049.
Texte intégralYadav, Hemang, Alastair C. Carr et Philippe R. Bauer. « Oncological Aspects of Respiratory Critical Care ». Dans Oxford Textbook of Respiratory Critical Care, 437–44. Oxford University PressOxford, 2023. http://dx.doi.org/10.1093/med/9780198766438.003.0049.
Texte intégralZekeridou, Anastasia. « “Restlessness” After Cancer Diagnosis and Treatment ». Dans Mayo Clinic Cases in Neuroimmunology, sous la direction de Andrew McKeon, B. Mark Keegan et W. Oliver Tobin, 157–59. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780197583425.003.0051.
Texte intégralT. Silveira, Fernando, Marliane B. Campos, Silvia F. Müller, Patrícia K. Ramos, Luciana V. Lima, Thiago V. dos Santos, Claudia Maria Gomes, Márcia D. Laurenti, Vania Lucia da Matta et Carlos Eduardo Corbett. « From Biology to Disease : Importance of Species-Specific Leishmania Antigens from the Subgenera Viannia (L. braziliensis) and Leishmania (L. amazonensis) in the Pathogenesis of American Cutaneous Leishmaniasis ». Dans Leishmania Parasites [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.108967.
Texte intégralActes de conférences sur le sujet "Immune check point inhibitor"
Lai, K., V. R. Shannon, D. Balachandran, A. Sheshadri, L. Bashoura et S. A. Faiz. « Role of Infliximab in Immune Check Point Inhibitor Induced Pneumonitis ». Dans American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4736.
Texte intégralIbraheim, Hajir, Lavinia Spain, Amit Samani, Sophie Papa, Nadia Yousaf, Martin Gore, James Larkin, Samra Turajlic et Nick Powell. « PWE-025 Microscopic colonic inflammation in immune check point inhibitor-induced diarrhoea/colitis ». Dans British Society of Gastroenterology, Annual General Meeting, 4–7 June 2018, Abstracts. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2018. http://dx.doi.org/10.1136/gutjnl-2018-bsgabstracts.157.
Texte intégralAlexander, S. A., V. Mathew Thomas, M. Singh et P. Premkumar. « A Fatal Case of Multisystem Organ Dysfunction Secondary to Immune Check Point Inhibitor Use ». Dans American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1714.
Texte intégralHutmacher-Berndt, Cornelia Deborah, et Dario Neri. « Abstract 3811 : Targeted Interleukin 2 and synergy with immune check-point inhibitors ». Dans Proceedings : AACR Annual Meeting 2018 ; April 14-18, 2018 ; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-3811.
Texte intégralSpain, Lavinia, Amit Samani, Hajir Ibraheim, Lewis Au, Zayd Tippu, Shuai Zhang, Sophie Merrick et al. « PTU-006 Incidence of immune check point inhibitor induced diarrhoea/colitis- experience from a multi-centre cohort ». Dans British Society of Gastroenterology, Annual General Meeting, 4–7 June 2018, Abstracts. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2018. http://dx.doi.org/10.1136/gutjnl-2018-bsgabstracts.128.
Texte intégralSasikumar, Pottayil G., Leena K. Satyam, Rajeev Shrimali, Raghuveer Ramachandra, Ketha A. Reddy, Adurthi Sreenivas, Amit Dhudashia, Dodderi S. Samiulla et Murali Ramachandra. « Abstract 1231 : Equipotent antagonism, transient immune activation and excellent antitumor efficacy with a peptide inhibitor of PD-1 immune check point pathway. » Dans Proceedings : AACR 104th Annual Meeting 2013 ; Apr 6-10, 2013 ; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-1231.
Texte intégralMitra, D. K., P. Kaur, G. Mehta, A. Mohan et M. Basil. « Immune Check Point Inhibitors in TB Patients : Impact on In-vitro Bacillary Clearance ». Dans American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a4870.
Texte intégralWong, Chi Wah, Susan E. Yost, Jin Sun Lee, Sarah K. Highlander et Yuan Yuan. « Abstract 336 : Gut microbiome predicts response to CDK4/6 inhibitor and immune check point inhibitor combination in patients with hormone receptor positive metastatic breast cancer ». Dans Proceedings : AACR Annual Meeting 2021 ; April 10-15, 2021 and May 17-21, 2021 ; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-336.
Texte intégralMiron Elorriaga, G., Y. Viseda Torrellas, M. Palacios Filardo, M. Cardenas Sierra, FJ Goikolea Ugarte, A. Martin Torrente, L. Torio Alvarez et al. « 5PSQ-112 Relationship between effectiveness and immune-mediated toxicity of immune check-point inhibitors in advanced non-small-cell lung cancer ». Dans 27th EAHP Congress, Lisbon, Portugal, 22-23-24 March 2023. British Medical Journal Publishing Group, 2023. http://dx.doi.org/10.1136/ejhpharm-2023-eahp.454.
Texte intégralMcKenzie, Andrew, Nektaria Papadopoulou, Simon Jiang, Jane Wrigley, Kelly Jones, Russell Garland, Neil Williams et Rajendra Kumari. « Abstract A140 : Check point inhibitor modulation of tumor microenvironment at orthotopic and metastatic sites using bioluminescent syngeneic cell line models in immune competent mice ». Dans Abstracts : Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference : Translating Science into Survival ; September 25-28, 2016 ; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6066.imm2016-a140.
Texte intégral